Search - tctmd.com

Displaying 581 - 600 of 962

Sort: Relevancy | Date

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

No More Absorb BVS: Abbott Puts a Stop to Sales

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

September 08, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

News Daily News

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

August 15, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

News Daily News

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

Yael L. Maxwell

August 14, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.